- Home
- MBRX
as 02-21-2025 4:00pm EST
Moleculin Biotech Inc is a clinical stage pharmaceutical company focused on the development of a broad portfolio of drug candidates for the treatment of resistant tumors and viruses. The company's Annamycin program is a next-generation anthracycline designed to avoid multidrug resistance mechanisms with little to no cardiotoxicity.
| Founded: | 2015 | Country: | United States |
| Employees: | N/A | City: | HOUSTON |
| Market Cap: | 1.4M | IPO Year: | 2016 |
| Target Price: | $24.00 | AVG Volume (30 days): | 13.3M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.22 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.40 - $6.24 | Next Earning Date: | 03-21-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest Moleculin Biotech Inc. News
MBRX Breaking Stock News: Dive into MBRX Ticker-Specific Updates for Smart Investing
MT Newswires
10 days ago
Moleculin Biotech Expects to Raise $5.8 Million From Exercise of Warrants
Benzinga
10 days ago
Why Is Blood Cancer Focused Moleculin Biotech Stock Trading More Than 400% On Thursday?
PR Newswire
10 days ago
Moleculin Announces Exercise of Warrants for $5.8 Million Gross Proceeds
PR Newswire
10 days ago
Moleculin Receives Positive FDA Guidance for Acceleration of its Registration-Enabling MIRACLE Trial for R/R Acute Myeloid Leukemia (AML)
Clinical Trials Arena
11 days ago
Moleculin Biotech gains approval for enrolment in trial of AML therapy in Ukraine
MT Newswires
12 days ago
Moleculin Biotech Receives Approval in Ukraine to Start Recruiting for Acute Myeloid Leukemia Phase 3 Trial
PR Newswire
12 days ago
Moleculin Receives First Country Approval in Europe to Begin Recruiting for the MIRACLE Phase 3 R/R Acute Myeloid Leukemia (AML) Pivotal Trial
PR Newswire
a month ago
Moleculin Participates in Virtual Investor "What This Means" Segment
Compare MBRX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "MBRX Moleculin Biotech Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.